{"id":"gsk3389404","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in type I and type III interferon signaling and IL-23 signaling pathways. By selectively inhibiting TYK2, GSK3389404 reduces the activation and proliferation of pathogenic T cells and other immune cells involved in inflammatory and autoimmune diseases. This selective approach aims to provide efficacy while potentially minimizing some of the broader immunosuppressive effects associated with pan-JAK inhibition.","oneSentence":"GSK3389404 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:40:00.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT03020745","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-14","conditions":"Hepatitis B","enrollment":78},{"nctId":"NCT02647281","phase":"PHASE1","title":"First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-17","conditions":"Hepatitis B","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK3389404","genericName":"GSK3389404","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK3389404 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses. Used for Psoriasis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}